Importer of Controlled Substances Registration: Almac Clinical Services Incorp (ACSI), 27473 [2016-10730]

Download as PDF Federal Register / Vol. 81, No. 88 / Friday, May 6, 2016 / Notices maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above-named company is granted registration as an importer of marihuana (7360), a basic class of controlled substance listed in schedule I. The company plans to import finished pharmaceutical products containing cannabis extracts in dosage form for clinical trial studies. This compound is listed under drug code 7360. No other activity for this drug code is authorized for this registration. Approval of permits applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale. Dated: April 29, 2016. Louis J. Milione, Deputy Assistant Administrator. [FR Doc. 2016–10728 Filed 5–5–16; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Manufacturer of Controlled Substances Registration: Noramco, Inc. ACTION: Noramco, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Noramco, Inc. registration as a manufacturer of those controlled substances. SUMMARY: By notice dated November 23, 2015, and published in the Federal Register on December 3, 2015, 80 FR 75692, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801– 4417 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc. to asabaliauskas on DSK3SPTVN1PROD with NOTICES VerDate Sep<11>2014 17:20 May 05, 2016 Jkt 238001 Controlled substance Codeine-N-oxide (9053) ............... Dihydromorphine (9145) ............... Morphine-N-oxide (9307) ............. Amphetamine (1100) .................... Methylphenidate (1724) ................ Phenylacetone (8501) .................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) .................. Opium, powdered (9639) ............. Opium, granulated (9640) ............ Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Tapentadol (9780) ........................ Schedule I I I II II II II II II II II II II II II II II II II II II II The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. Notice of registration. SUPPLEMENTARY INFORMATION: manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the following basic classes of controlled substances: Dated: April 29, 2016. Louis J. Milione, Deputy Assistant Administrator. [FR Doc. 2016–10731 Filed 5–5–16; 8:45 am] BILLING CODE 4410–09–P 27473 grants Almac Clinical Services Incorp (ACSI) registration as an importer of this controlled substance. SUPPLEMENTARY INFORMATION: By notice dated December 15, 2015, and published in the Federal Register on December 24, 2015, 80 FR 80387, Almac Clinical Services Incorp (ACSI), 25 Fretz Road, Souderton, Pennsylvania 18964 applied to be registered as an importer of a certain basic class of controlled substance. No comments or objections were submitted for this notice. The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of Almac Clinical Services Incorp (ACSI) to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above-named company is granted registration as an importer of Morphine (9300), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance in dosage form for clinical trial only. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale. Dated: April 29, 2016. Louis J. Milione, Deputy Assistant Administrator. [FR Doc. 2016–10730 Filed 5–5–16; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration DEPARTMENT OF JUSTICE [Docket No. DEA–392] Drug Enforcement Administration Importer of Controlled Substances Registration: Almac Clinical Services Incorp (ACSI) [Docket No. DEA–392] ACTION: Notice of registration. Almac Clinical Services Incorp (ACSI) applied to be registered as an importer of a certain basic class of controlled substance. The Drug Enforcement Administration (DEA) SUMMARY: PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 Importer of Controlled Substances Registration: Noramco, Inc. ACTION: Notice of registration. Noramco, Inc. applied to be registered as an importer of certain basic classes of controlled substances. The Drug Enforcement Administration SUMMARY: E:\FR\FM\06MYN1.SGM 06MYN1

Agencies

[Federal Register Volume 81, Number 88 (Friday, May 6, 2016)]
[Notices]
[Page 27473]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-10730]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Registration: Almac Clinical 
Services Incorp (ACSI)

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Almac Clinical Services Incorp (ACSI) applied to be registered 
as an importer of a certain basic class of controlled substance. The 
Drug Enforcement Administration (DEA) grants Almac Clinical Services 
Incorp (ACSI) registration as an importer of this controlled substance.

SUPPLEMENTARY INFORMATION: By notice dated December 15, 2015, and 
published in the Federal Register on December 24, 2015, 80 FR 80387, 
Almac Clinical Services Incorp (ACSI), 25 Fretz Road, Souderton, 
Pennsylvania 18964 applied to be registered as an importer of a certain 
basic class of controlled substance. No comments or objections were 
submitted for this notice.
    The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 
958(a) and determined that the registration of Almac Clinical Services 
Incorp (ACSI) to import the basic class of controlled substance is 
consistent with the public interest and with United States obligations 
under international treaties, conventions, or protocols in effect on 
May 1, 1971. The DEA investigated the company's maintenance of 
effective controls against diversion by inspecting and testing the 
company's physical security systems, verifying the company's compliance 
with state and local laws, and reviewing the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above-named company is granted 
registration as an importer of Morphine (9300), a basic class of 
controlled substance listed in schedule II.
    The company plans to import the listed controlled substance in 
dosage form for clinical trial only. Approval of permit applications 
will occur only when the registrant's business activity is consistent 
with what is authorized under 21 U.S.C. 952(a)(2). Authorization will 
not extend to the import of FDA approved or non-approved finished 
dosage forms for commercial sale.

    Dated: April 29, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016-10730 Filed 5-5-16; 8:45 am]
 BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.